Published in Blood on October 15, 1993
The colony-stimulating factors and cancer. Nat Rev Cancer (2010) 1.44
G-CSF and GM-CSF in Neutropenia. J Immunol (2015) 0.98
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Support Care Cancer (2014) 0.84
Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis (1994) 0.82
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer (2006) 0.81
Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. Br J Cancer (1996) 0.81
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. Br J Cancer (2008) 0.80
Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur J Clin Microbiol Infect Dis (1994) 0.79
Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? Br J Cancer (2004) 0.78
Hematopoietic growth factors in cancer patients with invasive fungal infections. Eur J Clin Microbiol Infect Dis (1997) 0.78
Haemopoietic growth factors. Postgrad Med J (1997) 0.77
Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis (1994) 0.77
Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis. Eur J Clin Microbiol Infect Dis (1994) 0.77
Biological response modifiers in cancer. MedGenMed (2006) 0.76
Beyond supportive care: what are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy? Blood (1993) 0.76
Questions about the role of granulocyte-macrophage colony-stimulating factor as adjunct to non-Hodgkin's lymphoma chemotherapy. Blood (1994) 0.75
Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst (2011) 0.75
Formation of bimolecular membranes from lipid monolayers and a study of their electrical properties. Proc Natl Acad Sci U S A (1972) 13.97
DNA N-glycosidases: properties of uracil-DNA glycosidase from Escherichia coli. J Biol Chem (1977) 7.24
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98
Development of K+-Na+ discrimination in experimental bimolecular lipid membranes by macrocyclic antibiotics. Biochem Biophys Res Commun (1967) 4.77
A molecular model of membrane excitability. J Supramol Struct (1974) 4.60
Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood (1997) 4.36
Studies on lysosomes. XI. Characterization of a hydrolase-rich fraction from human lymphocytes. J Cell Biol (1968) 4.22
Action potentials induced in biomolecular lipid membranes. Nature (1968) 3.71
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 3.53
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 3.50
Sporadic urban leptospirosis. Ann Intern Med (1996) 3.48
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 3.24
Light-driven protonation changes of internal aspartic acids of bacteriorhodopsin: an investigation by static and time-resolved infrared difference spectroscopy using [4-13C]aspartic acid labeled purple membrane. Biochemistry (1985) 3.08
Induced excitability in reconstituted cell membrane structure. J Theor Biol (1963) 2.96
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40
Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res (1996) 2.35
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol (1997) 2.28
Resting and action potentials in experimental bimolecular lipid membranes. J Theor Biol (1968) 2.22
Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet (1992) 2.21
Action potential phenomena in experimental bimolecular lipid membranes. Nature (1967) 2.15
Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst (1993) 2.14
A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer (1995) 2.12
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol (1993) 2.02
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood (1998) 1.80
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol (1996) 1.77
Different real-time PCR formats compared for the quantitative detection of human cytomegalovirus DNA. Clin Chem (1999) 1.77
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol (1998) 1.77
Solubilization of the Epstein-Barr virus-determined nuclear antigen and its characterization as a DNA-binding protein. J Virol (1977) 1.75
Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia (2004) 1.64
The primary structure of sensory rhodopsin II: a member of an additional retinal protein subgroup is coexpressed with its transducer, the halobacterial transducer of rhodopsin II. Proc Natl Acad Sci U S A (1995) 1.62
Spectrally silent transitions in the bacteriorhodopsin photocycle. Biophys J (1996) 1.62
Time-resolved detection of transient movement of helix F in spin-labelled pharaonis sensory rhodopsin II. J Mol Biol (2000) 1.60
Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet (1991) 1.60
Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood (1998) 1.59
Studies on lysosomes. XII. Redistribution of acid hydrolases in human lymphocytes stimulated by phytohemagglutinin. J Cell Biol (1968) 1.58
Asp85 is the only internal aspartic acid that gets protonated in the M intermediate and the purple-to-blue transition of bacteriorhodopsin. A solid-state 13C CP-MAS NMR investigation. FEBS Lett (1992) 1.57
The photophobic receptor from Natronobacterium pharaonis: temperature and pH dependencies of the photocycle of sensory rhodopsin II. Biophys J (1998) 1.55
Translation of avian myeloblastosis virus RNA in a cell-free lysate of Escherichia coli. Proc Natl Acad Sci U S A (1972) 1.53
Detection of herpesvirus type 6 by polymerase chain reaction in blood donors: random tests and prospective longitudinal studies. Br J Haematol (1994) 1.53
Bioenergetics of the Archaea. Microbiol Mol Biol Rev (1999) 1.52
Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry (2001) 1.52
Electrophysiological characterization of specific interactions between bacterial sensory rhodopsins and their transducers. Proc Natl Acad Sci U S A (2001) 1.51
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res (2001) 1.48
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia (2003) 1.47
Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol (1991) 1.47
Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria. Diabetes Care (1997) 1.45
Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer (1999) 1.44
Pneumococcal arthritis after allogeneic bone marrow transplantation. Bone Marrow Transplant (1993) 1.43
Interference of blood leucocytes in the measurements of immature red cells (reticulocytes) by two different (semi-) automated flow-cytometry technologies. Clin Lab Haematol (1996) 1.42
Membrane excitation through voltage-induced aggregation of channel precursors. Ann N Y Acad Sci (1975) 1.42
Selective susceptibility of CD34-expressing cells to acquire flow cytometric features of apoptosis/necrosis on exposure to an ammonium chloride-based red blood cell lysing reagent. J Hematother (1998) 1.42
Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol (1996) 1.40
Detection of somatic changes in human renal cell carcinomas with oligonucleotide probes specific for simple repeat motifs. Genes Chromosomes Cancer (1993) 1.40
Subtypes of T-cell chronic lymphatic leukemia. Cancer (1983) 1.39
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol (1996) 1.38
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs (2000) 1.37
Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin Chem (1999) 1.35
Transient kinetic studies on the interaction of Ras and the Ras-binding domain of c-Raf-1 reveal rapid equilibration of the complex. Biochemistry (1998) 1.35
Dipole moment of alamethicin as related to voltage-dependent conductance in lipid bilayers. Biophys J (1982) 1.34
Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother (1994) 1.34
Human herpesvirus 6A DNA Is detected frequently in plasma but rarely in peripheral blood leukocytes of patients after bone marrow transplantation. J Infect Dis (2000) 1.34
Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol (1997) 1.33
Purification of histidine tagged bacteriorhodopsin, pharaonis halorhodopsin and pharaonis sensory rhodopsin II functionally expressed in Escherichia coli. FEBS Lett (1999) 1.33
Structural insights into the early steps of receptor-transducer signal transfer in archaeal phototaxis. EMBO J (2001) 1.33
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant (2003) 1.31
Template activity of nuclei from stimulated lymphocytes. Nature (1969) 1.31
Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab (1993) 1.31
Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. Br J Haematol (1982) 1.30
Formation and properties of cell-size lipid bilayer vesicles. Biophys J (1983) 1.30
Blue halorhodopsin from Natronobacterium pharaonis: wavelength regulation by anions. Biochemistry (1994) 1.28
Sensory rhodopsin II from the haloalkaliphilic natronobacterium pharaonis: light-activated proton transfer reactions. Biophys J (2000) 1.27
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res (1991) 1.25
Detection of human cytomegalovirus DNA by real-time quantitative PCR. J Clin Microbiol (2000) 1.24
Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol (1995) 1.24
Biochemical and photochemical properties of the photophobic receptors from Halobacterium halobium and Natronobacterium pharaonis. Eur J Biochem (1992) 1.23
Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol (1999) 1.22
Protons suppress the dark current of frog retinal rods. J Physiol (1984) 1.20
Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood (1994) 1.20
Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol (1994) 1.19
High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol (2002) 1.19
Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol (1984) 1.17
A sensitive fluorescence monitor for the detection of activated Ras: total chemical synthesis of site-specifically labeled Ras binding domain of c-Raf1 immobilized on a surface. Chem Biol (2001) 1.17
Porous silicon as a versatile platform for laser desorption/ionization mass spectrometry. Anal Chem (2001) 1.16
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 1.15
Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol (1998) 1.15
The primary structure of halocyanin, an archaeal blue copper protein, predicts a lipid anchor for membrane fixation. J Biol Chem (1994) 1.14
Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant (2000) 1.14